Parkinson's incidence set to double as gene therapy pipeline advances

Parkinson's disease is growing faster than any other neurological condition worldwide, with incidence projected to double in the coming decades, according to a physician and scientist with more than 20 years specializing in the disease. Singer-songwriter Carly Simon's recent public diagnosis has drawn renewed attention to a condition with no cure and a treatment pipeline still working through basic biology. The next confirmable development is clinical evidence from investigational gene therapy programs now in progress.

The knowledge gap compounds the treatment gap. The Dana Foundation found brain health ranks as a top priority for Americans, but 66% of respondents report little or no knowledge about brain health research, with older Americans registering the lowest awareness. Those living with Parkinson's face a progressive disorder affecting the brain, nervous system, and muscle control, and current pills and symptomatic therapies, while helpful, do not stop the disease from worsening over time.

What the numbers show

At least 2.5 hours of consistent exercise per week has been shown to slow symptom progression and improve physical and emotional well-being for those living with the disease. Studies also link high levels of regular physical activity to a better clinical course. That is not a small variable in a condition where daily function and independence are what patients and families track most closely. Heart-healthy habits, including a well-balanced diet, quality sleep, and not smoking, also protect the small blood vessels that supply oxygen to energy-demanding brain cells, the physician noted.

The pipeline

The physician described involvement with an investigational gene therapy aimed at halting disease progression, with a goal of helping patients maintain or improve motor symptoms so that daily activities remain manageable compared with later-stage disease. Scientists in academia and industry are advancing molecular neuroscience, gene delivery methods, imaging, and biomarkers. None of those efforts have yet resolved the condition's complexity and unpredictability, as the physician acknowledged. The Michael J. Fox Foundation provides support for patients navigating the decision to disclose a diagnosis publicly. Clinical results from current gene therapy programs are the next concrete milestone.